All the news

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ...

Several cheap interventions can significantly boost engagement with the continuum of care for viral hepatitis, a systematic literature review and a series of meta-analyses published in The Lancet Infectious Diseases show. Programmes led by ...

Hepatitis B virus (HBV) could be eliminated as a global health threat with a scale-up of vaccination coverage, enhanced efforts to prevent vertical (mother-to-child) transmission and expansion of testing and treatment, according to ...

People with HIV and hepatitis B virus (HBV) co-infection have more than double the risk of death if they have ongoing high-level HBV replication, indicating a need for prompt treatment, according to an ...

People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have a higher rate of malignancies overall, but did show an increased incidence of colorectal and cervical cancer, underlining the ...